This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| MSK-IMPACT | |
|---|---|
| Name | MSK-IMPACT |
| Type | Clinical next-generation sequencing assay |
| Developer | Memorial Sloan Kettering Cancer Center |
| Introduced | 2014 |
| Purpose | Tumor genomic profiling for targeted therapy selection |
| Technology | Hybridization capture, next-generation sequencing |
MSK-IMPACT is a targeted next-generation sequencing assay developed for comprehensive tumor genomic profiling to guide precision oncology care at Memorial Sloan Kettering Cancer Center, with deployment in clinical laboratories and research studies. It was designed to detect single-nucleotide variants, indels, copy-number alterations, and select structural rearrangements across hundreds of cancer-associated genes to inform treatment decisions, clinical trial enrollment, and translational research. The assay links molecular findings to actionable targets, companion diagnostics, and biomarker-driven protocols at institutions such as Dana-Farber Cancer Institute, Johns Hopkins Hospital, Mayo Clinic, University of Texas MD Anderson Cancer Center, and regulatory bodies including the Food and Drug Administration.
MSK-IMPACT originated at Memorial Sloan Kettering Cancer Center under investigators affiliated with the Human Oncology and Pathogenesis Program, involving collaborators from Broad Institute, Cold Spring Harbor Laboratory, Weill Cornell Medicine, Columbia University Irving Medical Center, Yale School of Medicine, and industry partners like Illumina and Thermo Fisher Scientific. The panel has been iteratively expanded to include genes implicated in malignancies characterized at centers such as Cleveland Clinic, University of California, San Francisco, Stanford University School of Medicine, Harvard Medical School, and Princeton University collaborations. Early high-profile adopters included oncology groups at Memorial Sloan Kettering Cancer Center and cooperative groups like SWOG and NCI-CONNECT, integrating data with consortia such as AACR Project GENIE and registries like The Cancer Genome Atlas.
Development leveraged expertise from investigators previously associated with projects at the Broad Institute and technology platforms developed by Illumina and computational pipelines from Center for Cancer Systems Therapeutics teams. The assay uses hybrid-capture probes designed with inputs from laboratories at Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Vanderbilt University Medical Center, and engineering groups at Harvard Medical School. Bioinformatic workflows incorporated variant callers and copy-number tools popularized by groups at Massachusetts Institute of Technology, University of California, Los Angeles, University of Michigan, Fred Hutchinson Cancer Research Center, and software frameworks from Genome Analysis Toolkit contributors. Quality-control and laboratory standards were informed by protocols at American College of Pathologists, College of American Pathologists, Clinical Laboratory Improvement Amendments-accredited facilities, and translational teams at Memorial Sloan Kettering Cancer Center.
Clinically, MSK-IMPACT is used to identify therapeutically actionable alterations linked to targeted agents and immunotherapies developed by pharmaceutical companies including Roche, Pfizer, Merck & Co., AstraZeneca, and Novartis. The assay supports enrollment in trials run by cooperative groups such as NCI, EORTC, European Society for Medical Oncology-affiliated networks, and industry-sponsored protocols at centers like MD Anderson Cancer Center and Moffitt Cancer Center. Indications span solid tumors encountered at referral centers like Memorial Sloan Kettering Cancer Center, pediatric oncology programs at St. Jude Children's Research Hospital, sarcoma services at Royal Marsden Hospital, and central nervous system oncology units at Mayo Clinic and Johns Hopkins Hospital. Results are interpreted in the context of clinical guidelines from National Comprehensive Cancer Network, consensus statements from ASCO, and biomarker frameworks referenced by ESMO.
Analytical validation was reported in studies involving collaborators from Broad Institute, Dana-Farber Cancer Institute, and pathology laboratories at Columbia University, using reference materials and orthogonal methods developed by groups at NIST and sequencing centers such as European Genome-phenome Archive contributors. Performance characteristics—sensitivity, specificity, limit of detection—were benchmarked against assays from Foundation Medicine, Guardant Health, and academic panels at Memorial Sloan Kettering Cancer Center and University of Chicago. Limitations include detection gaps similar to those noted by investigators at University of Pennsylvania and University of California, San Diego for low-frequency subclonal variants, complex structural rearrangements characterized by teams at Cold Spring Harbor Laboratory, and epigenetic or transcriptomic alterations profiled by Broad Institute transcriptomics efforts.
Implementation in clinical laboratories followed routes used by other diagnostics reviewed by the Food and Drug Administration and overseen by accreditation bodies such as Centers for Medicare & Medicaid Services under CLIA frameworks adopted by institutions including Yale School of Medicine and Johns Hopkins Hospital. MSK-IMPACT results have been integrated into electronic health record systems deployed by vendors like Epic Systems Corporation and Cerner Corporation at centers such as Massachusetts General Hospital and Brigham and Women's Hospital to facilitate tumor boards modeled on multidisciplinary conferences at Memorial Sloan Kettering Cancer Center and UCSF Medical Center.
MSK-IMPACT contributed data to large-scale initiatives including The Cancer Genome Atlas, AACR Project GENIE, and collaborations with groups at Harvard Medical School, Broad Institute, Cold Spring Harbor Laboratory, and Stanford University. The assay accelerated discovery of recurrent driver mutations reported alongside work from investigators at Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, University of Cambridge, University of Oxford, and facilitated translational studies linking genomic alterations to therapies developed by Roche, Pfizer, AstraZeneca, and Merck & Co.. It influenced biomarker-driven trial designs at NCI and informed precision medicine programs at health systems including Kaiser Permanente and academic centers such as Yale School of Medicine.
Ethical and legal discussions around tumor profiling referenced frameworks from National Institutes of Health, Office for Human Research Protections, Institutional Review Board practices at Memorial Sloan Kettering Cancer Center and policy analyses by groups at Harvard T.H. Chan School of Public Health and Georgetown University. Economic evaluations compared cost-effectiveness versus assays from Foundation Medicine and circulating tumor DNA tests by Guardant Health with health-technology assessments considered by agencies like National Institute for Health and Care Excellence and payers including Centers for Medicare & Medicaid Services.